W Wolfgang Fleischhacker1. 1. Medical University Innsbruck, Department of Psychiatry and Psychotherapy, Anichstrasse 35, A-6020 Innsbruck, Austria. wolfgang.fleischhacker@i-med.ac.at
Abstract
BACKGROUND: Second-generation antipsychotics (SGAs) represent an advance in the long-term management of schizophrenia. AIMS: To review the available evidence concerning SGA long-acting injections (LAIs). METHOD: A systematic review of the literature was conducted using PubMed. RESULTS: Risperidone long-acting injection was the first licensed SGA-LAI compound and is effective in the long-term management of schizophrenia, with a safety profile similar to that of oral risperidone. Olanzapine pamoate has recently been approved in Europe. In terms of efficacy, at injection intervals of up to 4 weeks it appears comparable to oral olanzapine, although the potential for ;post-injection syndrome' (delirium) calls for additional safety considerations. Paliperidone palmitate is currently under review with the licensing authorities. It also affords the potential advantage of monthly dosing. CONCLUSIONS: More long-term comparisons of SGA-LAIs with oral SGAs as well as with first-generation antipsychotic LAIs are needed. These studies should include cost-effectiveness data.
BACKGROUND: Second-generation antipsychotics (SGAs) represent an advance in the long-term management of schizophrenia. AIMS: To review the available evidence concerning SGA long-acting injections (LAIs). METHOD: A systematic review of the literature was conducted using PubMed. RESULTS:Risperidone long-acting injection was the first licensed SGA-LAI compound and is effective in the long-term management of schizophrenia, with a safety profile similar to that of oral risperidone. Olanzapine pamoate has recently been approved in Europe. In terms of efficacy, at injection intervals of up to 4 weeks it appears comparable to oral olanzapine, although the potential for ;post-injection syndrome' (delirium) calls for additional safety considerations. Paliperidone palmitate is currently under review with the licensing authorities. It also affords the potential advantage of monthly dosing. CONCLUSIONS: More long-term comparisons of SGA-LAIs with oral SGAs as well as with first-generation antipsychotic LAIs are needed. These studies should include cost-effectiveness data.
Authors: Jimmi Nielsen; Signe O W Jensen; Rasmus B Friis; Jan B Valentin; Christoph U Correll Journal: Schizophr Bull Date: 2014-09-01 Impact factor: 9.306
Authors: Gregory Kruse; Bruce J O Wong; Mei Sheng Duh; Patrick Lefebvre; Marie-Hélène Lafeuille; John M Fastenau Journal: Pharmacoeconomics Date: 2015-10 Impact factor: 4.981